Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with lewy bodies

Journal of Alzheimer's Disease

Volumn 40, Issue 2, 2014, Pages 343-350

  Nielsen, Henrietta M ^a   Hall, Sara ^b,c   Surova, Yulia ^b,c   Nägga, Katarina ^d   Nilsson, Christer ^d   Londos, Elisabet ^d   Minthon, Lennart ^d   Hansson, Oskar ^d   Wennström, Malin ^d  

^a MAYO CLINIC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease markers; amyloid ; biomarker; cerebrospinal fluid; dementia with Lewy bodies; neurosin; NG2; Parkinson's disease; synucleinopathies; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; KALLIKREIN 6; NEURON GLIA 2; PROTEOGLYCAN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SYNUCLEINOPATHY; ANALYSIS OF VARIANCE; MENTAL HEALTH; MIDDLE AGED; PARKINSON DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANTIGENS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PROTEOGLYCANS; TAU PROTEINS;

EID: 84901926508     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132246     Document Type: Article

References (56)

1. Staugaitis SM, Trapp BD (2009) NG2-positive glia in the human central nervous system. Neuron Glia Biol 5, 35-44.
2. Nishiyama A (2001) NG2 cells in the brain: A novel glial cell population. Hum Cell 14, 77-82.
3. Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB (1991) The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 114, 359-371. (Pubitemid 21909807)
4. Asher RA, MorgensternDA, Properzi F, Nishiyama A, Levine JM, Fawcett JW (2005) Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol Cell Neurosci 29, 82-96. (Pubitemid 40603883)
5. Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB (1999) PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci 112(Pt 6), 905-915. (Pubitemid 29179323)
6. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB (1996) Interaction between NG2 proteoglycan and PDGF alpha-receptor onO2Aprogenitor cells is required for optimal response to PDGF. J Neurosci Res 43, 315-330. (Pubitemid 26054019)
7. Liu H, Shubayev VI (2011) Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Exp Neurol 231, 236-246.
8. Ozerdem U, Stallcup WB (2004) Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7, 269-276.
9. Fang X, BurgMA, Barritt D, Dahlin-Huppe K, Nishiyama A, Stallcup WB (1999) Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol Biol Cell 10, 3373-3387. (Pubitemid 29489568)
10. Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB (1999) PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci 112(Pt 6), 905-915. (Pubitemid 29179323)
11. Zhu X, Bergles DE, Nishiyama A (2008) NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development 135, 145-157. (Pubitemid 351201488)
12. Nielsen H, Ek D,Avdic U, Orbjorn C, Hansson O, Bank TNB, Veerhuis R, Rozemuller A, Brun A, Minthon L, Wennstrom M (2013) NG2 cells, a new trail for Alzheimer's disease mechanisms? Acta Neuropathol Commun 1, 7.
13. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
14. Brun A, Englund E (1986) A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 19, 253-262. (Pubitemid 16111074)
15. Englund E, Brun A (1990) White matter changes in dementia of Alzheimer's type: The difference in vulnerability between cell compartments. Histopathology 16, 433-439. (Pubitemid 20153969)
16. Desai BS, Schneider JA, Li JL, Carvey PM, Hendey B (2009) Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm 116, 587-597.
17. Verbeek MM, Otte-Holler I, Ruiter DJ, de Waal RM (1999) Human brain pericytes as a model system to study the pathogenesis of cerebrovascular amyloidosis in Alzheimer's disease. Cell Mol Biol 45, 37-46.
18. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, Rogaeva E, Black SE (2008) Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 65, 790-795. (Pubitemid 351831457)
19. Spillantini MG, Goedert M (2000) The alphasynucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920, 16-27. (Pubitemid 32056547)
20. Jendroska K, Lees AJ, Poewe W, Daniel SE (1996) Amyloid beta-peptide and the dementia of Parkinson's disease. Mov Disord 11, 647-653. (Pubitemid 26381934)
21. Gibb WR, Luthert PJ, Janota I, Lantos PL (1989) Cortical Lewy body dementia: Clinical features and classification. J Neurol Neurosurg Psychiatry 52, 185-192. (Pubitemid 19054192)
22. Kamagata K, Motoi Y, Abe O, Shimoji K, Hori M, Nakanishi A, Sano T, Kuwatsuru R, Aoki S, Hattori N (2012) White matter alteration of the cingulum in Parkinson disease with and without dementia: Evaluation by diffusion tensor tractspecific analysis. AJNR Am J Neuroradiol 33, 890-895.
23. Melzer TR,Watts R, Macaskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ (2013) White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 80, 1841-1849.
24. Shimoji K, Abe O, Uka T, Yasmin H, Kamagata K, Asahi K, Hori M, Nakanishi A, Tamura Y,Watada H, Kawamori R, Aoki S (2013) White matter alteration in metabolic syndrome: Diffusion tensor analysis. Diabetes Care 36, 696-700.
25. Yoshida M, Hori M, Yokoyama K, Fukunaga I, Suzuki M, Kamagata K, Shimoji K, Nakanishi A, Hattori N, Masutani Y, Aoki S (2013) Diffusional kurtosis imaging of normalappearing white matter in multiple sclerosis: Preliminary clinical experience. Jpn J Radiol 31, 50-55.
26. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99, 14-20. (Pubitemid 30093433)
27. Farkas E, De Jong GI, deVos RA, Jansen Steur EN, Luiten PG (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (Berl) 100, 395-402. (Pubitemid 30497009)
28. Jellinger KA, Attems J (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm 115, 473-482.
29. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, GalaskoD, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726.
30. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel- Doring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG (2013) Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 532, 44-48.
31. Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, Haruta H (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord 17, 395-397.
32. Wennstrom M, Londos E, Minthon L, Nielsen HM (2012) Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis 29, 125-132.
33. Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F, Hansson O, Nielsen HM (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8, e53250.
34. McKeith IG, DicksonDW,Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, YamadaM(2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
35. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J,Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124. (Pubitemid 26374873)
36. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
37. Armstrong RA, Cairns NJ (2009) Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology. Neurol Sci 30, 471-477.
38. Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, Van Eldik LJ, MarkesberyWR(2010) Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol 257, 1875-1881.
39. Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA (2012) Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79, 1161-1167.
40. Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Hakan W, Decraemer H, Nagga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69, 1445-1452.
41. Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E (2013) Lentivirus mediated delivery of neurosin promotes clearance of wild-type alphasynuclein and reduces the pathology in an alpha-synuclein model of LBD. Mol Ther 21, 31-41.
42. Tatebe H, Watanabe Y, Kasai T, Mizuno T, Nakagawa M, Tanaka M, Tokuda T (2010) Extracellular neurosin degrades alpha-synuclein in cultured cells. Neurosci Res 67, 341-346.
43. Bayani J, Diamandis EP (2012) The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med 50, 211-233.
44. Fukushi J, Makagiansar IT, Stallcup WB (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 15, 3580-3590. (Pubitemid 38989698)
45. Kucharova K, Chang Y, Boor A, Yong VW, Stallcup WB (2011) Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation 8, 158.
46. Moransard M, Dann A, Staszewski O, Fontana A, Prinz M, Suter T (2011) NG2 expressed by macrophages and oligodendrocyte precursor cells is dispensable in experimental autoimmune encephalomyelitis. Brain 134, 1315-1330.
47. Stallcup WB, Huang FJ (2008) A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr 2, 192-201.
48. Yamanaka H, He X, Matsumoto K, Shiosaka S, Yoshida S (1999) Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res 71, 217-224. (Pubitemid 29492966)
49. Terayama R, Bando Y, Takahashi T, Yoshida S (2004) Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 48, 91-101. (Pubitemid 39545941)
50. Terayama R, BandoY, JiangYP,Mitrovic B,Yoshida S (2005) Differential expression of protease M/neurosin in oligodendrocytes and their progenitors in an animal model of multiple sclerosis. Neurosci Lett 382, 82-87. (Pubitemid 40725870)
51. Biname F, Sakry D, Dimou L, Jolivel V, Trotter J (2013) NG2 regulates directional migration of oligodendrocyte precursor cells via Rho GTPases and polarity complex proteins. J Neurosci 33, 10858-10874.
52. de Castro R, Jr., Tajrishi R, Claros J, Stallcup WB (2005) Differential responses of spinal axons to transection: Influence of the NG2 proteoglycan. Exp Neurol 192, 299-309. (Pubitemid 40341676)
53. Dou CL, Levine JM (1994) Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J Neurosci 14, 7616- 7628. (Pubitemid 24379769)
54. Jones LL, Sajed D, Tuszynski MH (2003) Axonal regeneration through regions of chondroitin sulfate proteoglycan deposition after spinal cord injury: A balance of permissiveness and inhibition. J Neurosci 23, 9276-9288. (Pubitemid 37323026)
55. McTigue DM, Tripathi R,Wei P (2006) NG2 colocalizes with axons and is expressed by a mixed cell population in spinal cord lesions. J Neuropathol Exp Neurol 65, 406-420. (Pubitemid 44264837)
56. Stegmuller J, Werner H, Nave KA, Trotter J (2003) The proteoglycan NG2 is complexed with alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptors by the PDZ glutamate receptor interaction protein (GRIP) in glial progenitor cells. Implications for glial-neuronal signaling. J Biol Chem 278, 3590-3598. (Pubitemid 36801082)